ArticleDiscover oncology2025
miR-3613-5p promotes lung cancer progression by targeting and regulating XPO6.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMicroRNAs (miRNAs) exert a crucial role in the progression of lung cancer (LC) and can serve as prognostic biomarkers.
aimTo analyze the prognostic value of miR-3613-5p and its regulatory effect on XPO6 in LC, this study was conducted.
methodsThe expression of miR-3613-5p and XPO6 was detected using qRT-PCR. The miRDB database was employed to predict XPO6 as a target gene of miR-3613-5p, and a dual-luciferase reporter assay was further used to verify their interaction. Cell proliferation was assessed using the CCK-8, while cell migration and invasion were evaluated via the Transwell.
resultsmiR-3613-5p was notably overexpressed in LC, and its expression was notably associated with smoking history, TNM stage, tumor size, and lymph node metastasis. High miR-3613-5p expression was closely related to poor survival in patients diagnosed with LC, and miR-3613-5p could act as an independent prognostic factor. Database prediction results indicated that miR-3613-5p directly targets XPO6, which was further verified by the dual-luciferase reporter assay. Additionally, XPO6 could offset the promoting effect of miR-3613-5p.
conclusionThe miR-3613-5p-XPO6 axis may act as a LC therapeutic target, and novel therapeutic strategies for LC could be developed based on this axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.